Difference between revisions of "Tirabrutinib (Velexbru)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== BTK inhibitor ==Diseases for which it is used== *Waldenström macroglobulinemia ==History of changes in PMDA indication== *2020-08-21: new indica...") |
m |
||
| Line 7: | Line 7: | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2020-08-21: new indications for the treatment of [[Waldenström macroglobulinemia|Waldenström's macroglobulinemia]] and lymphoplasmacytic lymphoma. | *2020-08-21: new indications for the treatment of [[Waldenström macroglobulinemia|Waldenström's macroglobulinemia]] and lymphoplasmacytic lymphoma. | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' GS-4059 | ||
| + | *'''Brand name:''' Velexbru | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Revision as of 00:35, 7 June 2023
Mechanism of action
BTK inhibitor
Diseases for which it is used
History of changes in PMDA indication
- 2020-08-21: new indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma.
Also known as
- Code name: GS-4059
- Brand name: Velexbru